Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03130803 · ClinicalTrials.gov registry record · NA

Biomarkers of Insufficient Sleep and Sleepiness

A NA study of Sleep Deprivation and Sleep Wake Disorders, sponsored by University of Colorado, Boulder.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT03130803: Completed NA study of Sleep Deprivation and Sleep Wake Disorders, sponsored by University of Colorado, Boulder.

NCT03130803 is a NA study of Sleep Deprivation and Sleep Wake Disorders that has completed, run by University of Colorado, Boulder. The registered enrollment target is 12 participants, below the 91-participant average among 34 other Sleep Deprivation trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03130803, a NA study of Sleep Deprivation and Sleep Wake Disorders, has completed, sponsored by University of Colorado, Boulder.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Sleep and wakefulness disorders impact 50 to 70 million Americans and insufficient sleep is epidemic with over 50% of Americans reporting less than 7 hours of sleep per night. Health problems associated with insufficient sleep include inflammation, depression and anxiety, diabetes, stress, drug abuse, poor quality of life, obesity, and fatigue related accidents on the job/while driving. While the contribution of sleep to overall health, well-being, and public safety is recognized, no established clinical biomarkers of sleep deficiency exist. Such biomarkers would have utility as road-side biomarkers of sleepiness (e.g., drowsy driving), monitoring on the job fatigue/fitness for duty (e.g., transportation, military ops health care), monitoring sleep health, as well as for clinical diagnostics and measures of clinical treatment outcomes. Thus, investigators designed a controlled laboratory insufficient sleep protocol utilizing metabolomics to identify biomarkers of insufficient sleep. Investigators propose to identify changes in metabolites that consistently occur during insufficient sleep. As an exploratory outcome investigators will examine associated changes in metabolites and cognitive performance during insufficient sleep.

Primary Outcome

Investigators can detect \~4,000 plasma metabolites and will identify which metabolites have consistent, sensitive, and specific responses to insufficient sleep across visits one and two. These metabolites will be identified as candidate biomarkers of insufficient sleep.

Interventions

  • BEHAVIORAL Insufficient Sleep

Study Locations (1)

Colorado

  • Sleep and Chronobiology Laboratory - Boulder

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2017-01-19
Est. Completion 2019-02-22
Phase NA
University of Colorado, Boulder

69 total trials

What the finished NCT03130803 record still lists

NCT03130803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 91-participant average among 34 other Sleep Deprivation trials with a reported enrollment target (87% lower).

The record links to 3 conditions, with Sleep Deprivation appearing as the primary indexed condition, and to 1 intervention - of which Insufficient Sleep is the first listed.

NCT03130803 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT03130803 about?

NCT03130803 is a clinical study titled "Biomarkers of Insufficient Sleep and Sleepiness". Sleep and wakefulness disorders impact 50 to 70 million Americans and insufficient sleep is epidemic with over 50% of Americans reporting less than 7 hours of sleep per night. Health problems associated with insufficient sleep include inflammation, depression and anxiety, diabetes, stress, drug abus...

What is the current status of trial NCT03130803?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2017-01-19. Estimated completion is 2019-02-22.

What conditions does trial NCT03130803 study?

This clinical trial studies the following conditions: Sleep Deprivation, Sleep Wake Disorders, Insufficient Sleep Syndrome.

What interventions are being tested in trial NCT03130803?

The interventions under investigation include: Insufficient Sleep (BEHAVIORAL).

Who is sponsoring clinical trial NCT03130803?

This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03130803 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Deprivation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03130803's enrollment target sits among peer trials

12 32nd of 34 higher than 3 of 34 other Sleep Deprivation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sleep Deprivation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03130803, the US trial registry maintained by the National Library of Medicine. NCT03130803 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.